Eithne McShane
Director, Principal Consultant

Eithne McShane has 20 years national and international experience in the pharmaceutical and medical technology industry. She has held directorships and senior management roles in marketing & sales, market access and business development & licensing. Eithne has worked with a variety of companies from large, publically quoted companies such as Novartis and Bayer, to venture capital funded biotechs and privately held pharmaceutical companies.

Prior to establishing Fios Pharma, Eithne was Market Access Manager at Bayer where she had responsibility for market access strategy, price & reimbursement and health economic submissions across the company’s pharmaceutical portfolio which included drugs in oncology, women’s health, cardiology and rare disease.

In 2007, Eithne joined Therabel Europe – a privately held European pharmaceutical company with sales and marketing operations in Western Europe. As Director, Business Development, Eithne was part of the Business Development team that oversaw the expansion of the company into new geographic markets via a number of significant acquisitions and licensing deals. The most recent deal involved the acquisition of exclusive European commercialisation rights to a late stage oncology product with headline deal value of €48 million Euro. Eithne also had responsibility for managing post-deal integration activities, alliance management and out-licensing.

During the mid-noughties Eithne was Head of Marketing & Sales in Oncology for Novartis where she successfully oversaw a period of rapid expansion of the oncology business unit. Prior to Novartis, Eithne was International Marketing Manager for Biotrin International (now DiaSorin) and was responsible for successfully launching the company’s lead diagnostic product in the USA.

Eithne holds a B.Sc. (Hons) in Microbiology from the Queen’s University of Belfast, a M.B.A. from University College Dublin and a Diploma in Health Economics. She is a member of a number of professional societies including, the Pharmaceutical Licensing Group (PLG) for UK & Ireland, the International Society for Pharmacoeconomic Outcomes Research (ISPOR) and the Pharmaceutical Managers Institute of Ireland (PMI).